Botanix Pharmaceuticals reaches commercial milestone

Botanix Pharmaceuticals (ASX: BOT) has successfully issued the first prescriptions for its product Sofdra™ (sofpironium) topical gel, 12.45%. This marks a major milestone for the company as it transitions to a commercial-stage pharmaceutical entity. The initial prescriptions were part of the Sofdra Patient Experience Program in collaboration with the International Hyperhidrosis Society.

Botanix Pharmaceuticals' strategic progress and future outlook

Botanix Pharmaceuticals has announced the successful issuance of the first prescriptions for Sofdra, a significant milestone in their transition to a commercial-stage company. Sofdra is an FDA-approved treatment for excessive underarm sweating, providing a new option for patients with limited alternatives. The company has prepared extensively for the full commercial launch in Q1 2025, including inventory build-up, logistics testing, and staffing increases. Botanix has expanded its team, refined marketing strategies, and is finalizing insurance coverage arrangements. The company plans to provide future updates on prescription volumes and revenue growth, positioning itself to address the needs of patients with primary axillary hyperhidrosis.

Executive insights on Sofdra's launch

The issuance of the first prescriptions for Sofdra marks an important step in our journey to becoming a commercial-stage pharmaceutical company. We are excited about the upcoming full commercial launch in Q1 2025 and are confident that our preparations and team expansion will support a successful rollout.